Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure

H Arakawa, U Ikeda, Y Hojo, S Ueno, M Nonaka-Sarukawa, K Yamamoto, K Shimada

Growth factors play an important role in the pathogenesis of cardiovascular diseases by regulating cellular proliferation, migration, differentiation, and apoptosis. Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells, and has been reported to promote collateral formation in ischemic cardiac muscle and tissue repair after wounding. In animal models, transfer of the VEGF gene into ischemic limbs induces angiogenesis and improves tissue perfusion. Recently, Baumgartner and colleagues demonstrated that intramuscular injection of naked plasmid DNA encoding VEGF improved limb ischemia by promoting angiogenesis in patients with critical peripheral arterial disease. Pearlman and colleagues demonstrated that direct infusion of VEGF improved global left ventricular ejection fraction and regional wall motion after acute myocardial infarction in an animal model. VEGF also induces endothelium dependent relaxation in isolated canine coronary arteries and decreases arterial pressure in rats in vivo. We previously reported that elevation of VEGF concentrations in patients with acute myocardial infarction contributed to the improvement of left ventricular function. In the present study, we measured circulating VEGF concentrations in patients with congestive heart failure (CHF).

METHODS
We studied 41 patients (24 men and 17 women, mean (SEM) age 67.4 (1.8) years, range 34–86 years) admitted to Jichi Medical School Hospital for acute exacerbation of CHF (table 1). The diagnosis of heart failure was confirmed in all patients by clinical findings and non-invasive assessment of myocardial function. Left ventricular ejection fraction (LVEF) was determined by echocardiographic evaluation. The control group consisted of 12 healthy volunteers (7 men and 5 women, aged 62.7 (4.1) years, range 34–80 years) without cardiovascular disease. All patients and volunteers gave their written informed consent to participation in the study, and the protocol was approved by the ethics committee of Jichi Medical School.

We previously found that VEGF concentrations in plasma isolated using heparin as an anticoagulant were underestimated (10.0 (2.5) %) compared to those in serum isolated without heparin. Thus, blood samples were obtained without anticoagulants. Blood sampling was performed at admission (on day 1), and on days 7 and 14 after admission using a 21 gauge needle inserted into a large antecubital vein of the patients in the supine position. Serum was obtained by centrifugation and stored immediately at −80°C until assayed for VEGF. VEGF concentrations were determined using a specific enzyme linked immunosorbent assay kit (Amersham International, Buckinghamshire, UK). The standard curve was linear from 15.6 to 1000 pg/ml of VEGF. Concentrations of brain natriuretic peptide (BNP) were determined by radiimmunooassay using a specific anti-BNP antibody (SRL Inc, Tokyo, Japan). The sensitivity of BNP assay was 2.0 pg/ml.

Data are expressed as mean (SEM). Differences were analysed by the non-parametric Mann-Whitney U test.

Table 1 Characteristics of patients with congestive heart failure

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>CHF patients</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female (n)</td>
<td>24/17</td>
<td>12/10</td>
</tr>
<tr>
<td>Age (years)</td>
<td>67.4 (1.8)</td>
<td>62.7 (4.1)</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>39.0 (2.7)</td>
<td>55.0 (3.1)</td>
</tr>
<tr>
<td>BNP (pg/ml)</td>
<td>308 (45.1)</td>
<td>15.6 (3.8)</td>
</tr>
<tr>
<td>Underlying heart disease (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>14</td>
<td>7</td>
</tr>
<tr>
<td>Valvar heart disease</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Congenital heart disease</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Drugs (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrates</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>β Blockers</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Diuretics</td>
<td>29</td>
<td></td>
</tr>
</tbody>
</table>

ACE, angiotensin converting enzyme; BNP, brain natriuretic peptide; CHF, congestive heart failure; LVEF, left ventricular ejection fraction.

Figure 1 Changes in serum VEGF concentrations in patients with CHF. Serum was obtained from peripheral blood without using anticoagulants. The data on day 1 represent serum VEGF concentrations at admission. Serum VEGF concentrations in CHF patients (solid circles) at admission were significantly lower than those in control subjects (open circles). Values are expressed as mean (SEM). NS, not significant.

Abbreviations: BNP, brain natriuretic peptide; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; VEGF, vascular endothelial growth factor.
correlation between two parameters was assessed by the non-parametric Spearman rank correlation test. A probability of p < 0.05 was considered significant.

RESULTS
Figure 1 shows the time course of changes in serum VEGF concentrations in patients with CHF after admission. Serum VEGF concentrations in CHF patients at admission (mean 10.3 (4.4) pg/ml; median < 15.6 pg/ml) were significantly lower than those of control subjects (mean 68.7 (16.4) pg/ml; median 63.0 pg/ml) (p < 0.01). Serum VEGF concentrations in CHF patients went up after admission, and the concentrations on day 14 were not significantly different compared with those of control subjects. No correlations were observed between serum VEGF concentrations and LVEF (r = 0.13, p = 0.40) or BNP concentrations (r = −0.22, p = 0.17) at admission.

DISCUSSION
This study revealed a significant decrease in serum VEGF concentration in CHF patients compared with control subjects. The VEGF concentration at admission was not related to the severity of CHF (LVEF and BNP concentrations), and the mechanism by which circulating VEGF concentrations are decreased in CHF is unknown. It may be due to decreased VEGF production and/or enhanced VEGF clearance. Previously, Kraus and colleagues reported that VEGF concentrations in the hearts of patients with end stage dilative cardiomyopathy. Cheng and colleagues also reported that VEGF concentrations in the pleural fluid of patients with CHF were significantly reduced. These findings suggest that decreased circulating VEGF concentrations in CHF patients are caused by decreased VEGF production in the cardiovascular tissue. On the other hand, circulating VEGF binds to Flt-1 and KDR receptors for VEGF, which are expressed predominantly in vascular endothelial cells, and the clearance of circulating VEGF through these receptors may also be related in part to decreased serum VEGF concentrations in CHF patients.

In conclusion, decreased serum VEGF concentrations were found in CHF patients. However, the underlying heart disease of CHF patients was heterogeneous in this study and the precise mechanism responsible for the decreased serum VEGF concentrations is still unknown. Further studies are needed to clarify the relation between VEGF and CHF.

References


WEB TOP 10

www.heartjnl.com
These articles scored the most hits on Heart’s website during November 2002

1. Doppler echocardiographic assessment of valvar regurgitation
J D Thomas
December 2002;88:651–7. [Education in Heart]

2. Heart failure: aetiology, diagnosis, and treatment
C George

3. Management of cardiogenic shock complicating acute myocardial infarction
V Menon, JS Hochman
November 2002;88:531–7. [Education in Heart]

4. Fifth report on the provision of services for patients with heart disease
November 2002;88[suppl III]:iii1–iii56.

5. Treatment of atrial fibrillation
Y Blauw, IC Van Gelder, HGM Crijns
October 2002;88:432–7. [Education in Heart]

6. Pulmonary hypertension in the young
SG Haworth
December 2002;88:658–64. [Education in Heart]

7. Transfer for primary angioplasty: who and how?
M Dalby, G Montalescot
December 2002;88:570–2. [Review]

8. Angioplasty, bypass surgery or medical treatment: how should we decide?
JP Pell, MA Dervir
November 2002;88:451–2. [Viewpoint]

9. Patients with ventricular arrhythmias: who should be referred to an electrophysiologist?
JM Morgan
November 2002;88:544–50. [Education in Heart]

10. β Blockers in older persons with heart failure: tolerability and impact on quality of life
AJ Baxter, A Spensley, A Hildreth, G Karimova, JE O’Connor, CS Gray
December 2002;88:611–14. [Cardiovascular medicine]

Visit the Heart website for hyperlinks to these articles, by clicking on “Top 10 papers”

www.heartjnl.com